Regeneron, “Corona 19 Antibody” Prevention Phase 3 “No Symptoms”

Reporter Yoon So-young, biospectator

This article ‘Premium News Service BioS+’ Article.

‘REGEN-COV’, a simpler subcutaneous injection method than the intravenous injection method.. No infected people with’symptoms’

Following Eli Lilly, Regeneron also published clinical results that showed effects when preemptively using the COV 19 antibody’REGEN-COV’ developed by itself for prevention purposes. Lilly announced last week that the risk of infection from Corona 19 was reduced by 80% when the antibody’bamlanivimab (LY-CoV555)’, developed as a treatment for Corona 19, was used for prevention purposes.

On the 26th (local time), Regeneron announced the interim results of phase 3 clinical trials using REGEN-COV (casirivimab+imdevimab), a COVID-19 antibody treatment, as a’passive vaccine’. The clinical trial was conducted on 409 applicants who are at high risk of corona 19 infection, such as when there are corona 19 infected patients in the vicinity.

Patients who participated in the clinical trial received REGEN-COV 1200 mg or placebo by subcutaneous injection. In the case of’symptomatic infection’ in clinical results, no one in the group receiving REGEN-COV came out, and 8 in the placebo group showed 100% prevention efficiency. The total number of infected patients (asymptomatic + symptomatic infection) was 10 in the REGEN-COV group and 23 in the placebo group, and the overall prevention efficiency was calculated as about 50%.

Regeneron explained that it is also meaningful to have preventive efficiency, but it is also meaningful that there are no symptomatic infections among patients who have been treated with REGEN-COV who are infected with Corona 19. If you are infected with Corona 19 but have no symptoms, the amount of virus is less than those with symptoms, and the virus shedding period is shorter. Accordingly, the effect of Corona 19 on the patient and the people around him is also small….